CSL, Talecris Call Off $3.1B Deal Amid FTC Pressure
CSL Ltd. has called off its proposed $3.1 billion acquisition of rival Talecris Biotherapeutics in the face of allegations by the Federal Trade Commission that the deal would have reduced competition...To view the full article, register now.
Already a subscriber? Click here to view full article